Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurocrine Biosciences
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be willing and able to adhere to the study procedures, including all requirements at the study center, and return for the follow-up visit.
Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency.
Be on a stable steroid regimen.
Have elevated androgen levels.
Participants of childbearing potential must be abstinent or agree to use appropriate birth control during the study.
You may not be if
Have a diagnosis of any of the other forms of classic CAH.
Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy.
Have a clinically significant unstable medical condition or chronic disease other than CAH.
Have a history of cancer unless considered to be cured.
Have a known history of clinically significant arrhythmia or abnormalities on electrocardiogram (ECG).
Have a known hypersensitivity to any corticotropin-releasing hormone antagonist.
Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study.
Have current substance dependence or substance (drug) or alcohol abuse.
Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study.
Clareo Health | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
